Family history of cancer in first-degree relatives and risk of gastric cancer and its precursors in a Western population
- 158 Downloads
Family history may inform risks of gastric cancer and preneoplastic lesions.
We examined associations with history of cancer in first-degree relatives for 307 incident gastric cancer cases among 20,720 male smokers in a prospective study in Finland. Cox regression was used to calculate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI). Logistic regression was used to estimate odds ratios (OR) and 95% CIs for low serum pepsinogen, a marker of gastric atrophy.
Gastric cancer risk was associated with gastric cancer history in first-degree relatives overall (HR 1.56, 95% CI 1.15–2.12), in fathers (HR 1.67, 95% CI 1.09–2.55) and in siblings (HR 2.05, 95% CI 1.25–3.38). Associations were significant for noncardia (HR 1.83, 95% CI 1.30–2.57) but not cardia (HR 0.93, 95% CI 0.46–1.87) cancers, and marginal for both intestinal—(HR 1.53, 95% CI 0.92–2.55) and diffuse-type (HR 1.47, 95% CI 0.72–3.03) histologies. Family history of other cancer types was not associated with gastric cancer risk. Family history of gastric cancer was associated with low pepsinogen (OR 1.29, 95% CI 1.11–1.50).
Family history of gastric cancer is strongly associated with specific subtypes of gastric cancer as well as with gastric atrophy, a risk factor for developing this malignancy.
KeywordsFamily history Gastric cancer Gastric atrophy Risk factors Caucasians
This study was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The ATBC Study was supported by funding provided by the Intramural Research Program of the National Cancer Institute and US Public Health Service contracts [HHSN261201500005C].
Compliance with ethical standards
Human rights statement and informed consent
All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. The study was approved by the Institutional Review Boards of both the National Cancer Institute, Bethesda, Maryland, USA and the National Public Health Institute, Helsinki, Finland. All participants provided written informed consent.
Conflict of interest
The authors declare no conflict of interest.
- 13.The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol. 1994;4(1):1–10.Google Scholar
- 53.Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods, vol. xix. Belmont: Lifetime Learning Publications; 1982. p. 529.Google Scholar